KimKramerMD

Pediatric Hematology & Oncology • New York, NY

Physician

Overview of Dr. Kramer

Dr. Kim Kramer is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, and New York-Presbyterian Hospital. She received her medical degree from SUNY Upstate Medical University and has been in practice 28 years. She is one of 97 doctors at Memorial Sloan Kettering Cancer Center and one of 14 doctors at NYC Health + Hospitals / Bellevue who specialize in Pediatric Hematology & Oncology. She has more than 100 publications and over 500 citings.

Office
1275 York Avenue
New York, NY 10065
Book by Phone+1(231) 508-9985

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1993 - 1996
University of Rochester Medical CenterFellowship, Pediatric Hematology/Oncology, 1992 - 1993
University of Rochester Medical CenterResidency, Pediatrics, 1989 - 1992
SUNY Upstate Medical UniversityClass of 1989

Certifications & Licensure

NY State Medical License 1993 - 2026
NC State Medical License 2021 - 2022
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Start of enrollment: 1997 Apr 01
Completed
Phase 1
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Start of enrollment: 2004 Feb 05
Terminated
Phase 1
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Start of enrollment: 2006 Jan 01
Completed
Phase 2
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
ACTIVE_NOT_RECRUITING
PHASE4
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

A phase II trial of Naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in first complete remission.
Brian H Kushner, Shakeel Modak, Audrey Mauguen, Ellen M Basu, Kim Kramer
Clinical Cancer Research. 2025-03-11
Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma (DIPG).
Mark M Souweidane, Evan D Bander, Pat Zanzonico, Anne S Reiner, Nicole Manino
Neuro-Oncology. 2025-02-19
1 citations
Evolutionary Strategies AI Addresses Multiple Technical Challenges in Deep Learning Deployment: Proof-of-Principle Demonstration for Neuroblastoma Brain Metastasis Det...
Subhanik Purkayastha, Hrithwik Shalu, David Gutman, Andrei Holodny, Shakeel Modak
Journal of Imaging Informatics in Medicine. 2024-12-01

Lectures

Intraventricular radioimmunotherapy targeting B7H3 for CNS malignancies.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Y-mAbs Announces Update on Naxitamab and Omburtamab in NeuroblastomaOctober 16th, 2020
Y-mAbs Announces Positive Omburtamab Clinical DataOctober 28th, 2019
Finding a Cure for Children with CNS NeuroblastomaJuly 22nd, 2019
Join now to see all